Drugs / MTX
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03478111 Background | Mar 2018 → Jun 2019 | rheumatoid arthritis | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03478111 ↗ |
| Route | Oral | “MIX (methotrexate) will be oral administered at a dose of 7.5mg\~15mg weekly from Week 0 to 38” NCT03478111 ↗ |